基质金属蛋白酶及其抑制剂与心血管疾病

摘要

基质金属蛋白酶(matrix metalloproteinases,MMPs)是一个锌、钙依赖性的内肽酶家族,是细胞外基质(ECM)降解的主要介质,表达和激活都受到严密的调控。基质金属蛋白酶活性可以被组织金属蛋白酶抑制剂(tissue inhibitor of matrix metallopro-teinases,TIMPs)控制,进而降低其表达。基质金属蛋白酶与组织金属蛋白酶抑制剂比例适当是维持心脏正常运行的重要因素。基质金属蛋白酶与组织金属蛋白酶抑制剂共同维持细胞外基质的平衡并且基质金属蛋白酶还参与了许多心血管疾病的发生发展过程,合理调控 MMPs 的表达与活性有利于心血管疾病的治疗。%Matrix metalloproteinases,a family of endopeptidases which is relied on zinc and calium,is primary mediator to degrade Extra Cellular Matrix.The expression and activation of MMPs are under the precise control.The activity of Matrix metalloproteinases can be controlled by tissue inhibitor of matrix met-alloproteinases,and their expression can also be declined by TIMPs.The proper proportion of Matrix metal-loproteinases and tissue inhibitor of matrix metalloproteinases plays an important role in keeping normal op-eration of heart .MMPs and TIMPs keep the balance of ECM together.Then MMPs participate in the genesis and development of a variety of cardiovascular diseases,reasonable regulation of MMPs expression and activ-ity is benefit to the treatment of cardiovascular diseases.